ArticleFrontiers in microbiology2025
Molecular characterization of carbapenem-resistant and carbapenem-sensitive
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Imipenem-Induced Transcriptional Responses of Porin, Efflux Pumps, and Carbapenemase Genes in Clinical Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Genomic characterization of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Comparative genomic insights into carbapenem-resistant versus susceptibleFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to examine the variations in resistance genes, virulence genes, and drug susceptibility between carbapenem-resistant and carbapenem-susceptible Methods: A retrospective study was undertaken involving 39 Results: The CR-AB isolates demonstrated substantial resistance to ceftazidime, cefepime, ceftriaxone, ampicillin/sulbactam, tobramycin, gentamicin, and levofloxacin, while exhibiting moderate resistance to trimethoprim-sulfamethoxazole and amikacin. Conversely, the CS-AB isolates remained susceptible to all the aforementioned commonly utilized clinical antibiotics. Antimicrobial susceptibility testing indicated that 2.56% of the 39 Conclusion: The CR-AB isolates from the ICU in Ningbo demonstrate heightened resistance and virulence traits in comparison to the CS-AB isolates. The application of the efflux pump inhibitor PAβN markedly increases the susceptibility of CR-AB to ceftazidime/avibactam.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.